
==== Front
Ultrasonography
Ultrasonography
USG
Ultrasonography
2288-5919
2288-5943
Korean Society of Ultrasound in Medicine

39175218
10.14366/usg.24091
usg-24091
Original Article
Potential role of two-dimensional shear wave elastography, including liver stiffness measurement and dispersion slope, for management of chronic hepatitis B
http://orcid.org/0009-0002-7158-1140
Song Seung ju 1
http://orcid.org/0000-0001-5615-9721
Kim Youe Ree 1
http://orcid.org/0000-0001-5893-6571
Lee Young Hwan 1
http://orcid.org/0000-0003-2604-918X
Cho Eun Young 2
1 Department of Radiology, Wonkwang University Hospital, Wonkwang University College of Medicine, Iksan, Korea
2 Department of Internal Medicine, Wonkwang University Hospital, Wonkwang University College of Medicine, Iksan, Korea
Correspondence to: Youe Ree Kim, MD, Department of Radiology, Wonkwang University Hospital, 895 Muwang-ro, Iksan 54538, Korea Tel. +82-63-859-1920 Fax. +82-63-851-4749 E-mail: sweetynn@naver.com
9 2024
15 7 2024
43 5 384392
20 5 2024
14 7 2024
15 7 2024
Copyright © 2024 Korean Society of Ultrasound in Medicine (KSUM)
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose

This study assessed the use of liver stiffness (LS) and dispersion slope (DS) in classifying patients with chronic hepatitis B (CHB) by the necessity of antiviral treatment.

Methods

A retrospective review examined 249 patients with CHB (male:female, 107:142; mean age, 53±14 years) between April 2018 and March 2022. Patients for whom treatment was indicated, termed group 1, exhibited either serum alanine transaminase (ALT) and aspartate aminotransferase levels not exceeding five times the upper limit of normal and LS >13 kPa, or hepatitis B virus DNA >2,000 IU/mL and ALT >40 IU/L. The remaining patients comprised group 2 (treatment not required). In subgroup analysis, patients with LS <13 kPa were further examined.

Results

Overall, group 1 exhibited significantly higher LS (12.64±6.76 vs. 6.31±1.67 kPa, P<0.001) and DS (15.52±4.95 vs. 11.04±1.93 [m/s]/kHz, P<0.001) than group 2. In subgroup analysis, group 1 also demonstrated significantly higher values (LS: 8.05±2.12 vs 6.31±1.67 kPa, P<0.001, DS: 13.06±2.75 vs. 11.04±1.93 [m/s]/kHz, P<0.001). The areas under the curve (AUCs) for LS and DS in identifying group1 were 0.855 (95% confidence interval [CI], 0.80 to 0.90; P<0.001) and 0.810 (95% CI, 0.75 to 0.86; P<0.001), respectively. In subgroup analysis, the AUCs for LS and DS in identifying group 1 were 0.751 (95% CI, 0.69 to 0.81; P<0.001) and 0.711 (95% CI, 0.64 to 0.77; P<0.001), respectively. For identifying group 1, the AUCs for LS and DS did not differ significantly (P>0.05).

Conclusion

LS and DS assist in classifying patients with CHB by their need for antiviral treatment.

Liver
Fibrosis
Ultrasonography
Two-dimensional shear wave elastography
Hepatitis B
Key point

Liver stiffness and dispersion slope values, as measured by two-dimensional shear wave elastography, can be instrumental in identifying patients with hepatitis B who require treatment.
==== Body
pmcGraphic Abstract

Introduction

Patients with hepatitis B virus (HBV) infection face an increased risk of developing cirrhosis, which can lead to life-threatening complications such as portal hypertension, liver failure, and hepatocellular carcinoma (HCC) [1]. Approximately 50% of patients with HCC have chronic HBV infection, and 80% of these patients develop HCC in conjunction with cirrhosis [2,3]. The 2017 European Association for the Study of the Liver (EASL) guidelines indicate that outcomes depend not only on the timing of therapy relative to the natural course of the infection but also on the disease stage and the age of the patient at treatment initiation [4].

Chronic infection and hepatitis with ongoing inflammation are key features used to differentiate liver conditions. An accurate assessment of the stages of liver fibrosis and inflammation is crucial for the effective management of chronic hepatitis B (CHB) [5]. While liver biopsy is considered the reference standard for assessing liver fibrosis, its invasiveness and the risk of potential complications limit its use [6]. Liver stiffness (LS) measurement using two-dimensional shear wave elastography (2D-SWE) has become a widely accepted method for diagnosing liver fibrosis [5,7]. The updated statement of the Society of Radiologists in Ultrasound (SRU) presents LS guidelines for patients with viral hepatitis and alcoholic fatty liver disease. Under these recommendations, an LS measurement below 9 kPa in the absence of clinical symptoms allows for the exclusion of compensated advanced chronic liver disease (cACLD); conversely, an LS value above 13 kPa strongly suggests cACLD [8].

Liver tissue exhibits viscoelastic properties, and the propagation of shear waves within the liver depends on viscosity and elasticity [9]. Liver viscosity can be indicative of conditions such as fibrosis, necroinflammatory activity, and steatosis [10-12]. Viscosity introduces frequency-dependent changes in shear wave velocity, a phenomenon referred to as shear wave dispersion (SWD) [13,14]. The dispersion slope (DS) has been shown to correlate with liver necroinflammation in studies involving rats, liver transplant recipients, and patients with nonalcoholic steatohepatitis (NASH)/ nonalcoholic fatty liver disease, which was recently renamed to metabolic dysfunction-associated steatohepatitis/steatotic liver disease [10,12,15-17].

Nevertheless, the details of DS have not been thoroughly investigated, and it remains unclear whether its association is limited to liver necroinflammation or extends to other pathological changes such as fibrosis and steatosis. In prior research, incorporating DS as an additional mechanical parameter did not significantly improve the diagnostic performance of LS for chronic liver disease (CLD) [18]. Moreover, studies of CHB cohorts are rare. The authors speculated that LS and DS could represent meaningful indicators when the patient sample was limited to CHB alone. The purpose of this study was to assess the utility of LS and DS in classifying patients with CHB based on the need for antiviral therapy.

Materials and Methods

Compliance with Ethical Standards

The Institutional Review Board at Wonkwang University Hospital approved this retrospective study (IRB No. 2023-09-014). The board waived the requirement for written informed consent.

Study Design

This study was conducted between April 2018 and March 2022. Data were analyzed from patients with CHB who had not received prior treatment or were diagnosed for the first time. These patients had undergone liver function tests and ultrasound with 2D-SWE within 1 week of laboratory examinations.

The two groups were modified in accordance with the 2017 EASL guidelines and the 2020 updated consensus statement on liver elastography from the SRU [4,8]. According to the 2017 EASL guidelines, since patients with cirrhosis should receive antiviral treatment, cirrhosis should be evaluated using an LS value of 13 kPa or higher, which represents the rule-in criterion for cACLD. In the present study, patients requiring treatment (termed group 1) were those who met one of the following criteria: (1) the cACLD rule-in criteria as presented [8], in which serum alanine transaminase (ALT) and aspartate aminotransferase (AST) levels do not exceed five times the upper limit of normal and LS is greater than 13 kPa; or (2) HBV DNA levels exceeding 2,000 IU/mL and ALT levels above 40 IU/L, as per the modified 2017 EASL guidelines [4]. Group 2 (those not requiring treatment) consisted of patients who did not meet the criteria for group 1.

The analysis was conducted in two stages. The first stage centered on comparing the groups across the entire patient population, regardless of LS level. The second stage of the analysis was restricted to patients with LS values below 13 kPa, within which groups 1 and 2 were compared.

Two-Dimensional Shear Wave Elastography

Two board-certified abdominal radiologists with 20 and 6 years of experience (Y.H.L. and Y.R.K., respectively), evaluated the patients using 2D-SWE with an Aplio i800 Ultrasound System (Canon Medical Systems Corp., Tokyo, Japan) equipped with a 1-8 MHz convex transducer. For optimal intercostal visualization, patients were placed in the supine position with the right arm fully abducted [10,11]. The liver parenchyma was first examined using B-mode attenuation imaging, followed by 2D-SWE. A sample box measuring approximately 2.5×2.5 cm was positioned in the right liver lobe, 1 cm beneath the liver capsule, to avoid reverberation artifacts. Patients were asked to hold their breath for 4-5 seconds during the procedure. Once the sample box had gathered the necessary data, the ultrasound system switched to quad view mode, simultaneously displaying elasticity, propagation, and dispersion maps, along with a grayscale image [10,11]. The LS values, expressed in kilopascals (kPa), and the DS values, expressed in meters per second per kilohertz ([m/s]/kHz), corresponding to the Young modulus E, were obtained concurrently [10,11]. A 1-cm circular region of interest was then manually placed within the sample box. Shear wave propagation was initiated, and 9 to 12 2D-SWE images were captured for each patient. LS, shear wave speed, and DS, corresponding to the interquartile range-to-median ratio of ≤0.3, were assessed. The median values of LS and DS were used for analysis. In addition, the skin-to-liver capsule distances were retrospectively measured on the ultrasound images for all patients.

Clinical Data

Labolatory findings within 1 week before and after 2D-SWE examination were analyzed. The laboratory results included factors related to HBV, specifically hepatitis B surface antigen, hepatitis B surface antibodies, and HBV DNA titers. Measurements were obtained of serum AST, ALT, alkaline phosphatase, gamma-glutamyl transferase, albumin, total bilirubin, and platelet (PLT) levels. Fibrosis-4 index scores were calculated using the formula: age (y)×AST (U/L)/[PLT (109/L)×ALT1/2 (U/L)].

Medical records were reviewed to calculate body mass index and assess previous treatment status, as well as to gather other medical and social history information.

Statistical Analysis

Continuous variables describing patient characteristics are presented as means±standard deviations. These variables were compared between the two groups using an independent-samples t-test. The relationship between LS and DS was assessed through Pearson correlation analysis, both overall and by subgroup. The overall diagnostic performance of LS and DS for the treatment group was determined based on the area under the curve (AUC) of receiver operating characteristic (ROC) analysis, which were expressed with 95% confidence intervals (CIs). Specificity, sensitivity, and 95% CIs were calculated for the cutoff values of these two parameters, obtained using the Youden index. The AUCs of the ROC curves were compared between LS and DS using the DeLong method.

All data were statistically analyzed using SPSS version 26 (IBM Corp., Armonk, NY, USA) and MedCalc version 12.7.0 (MedCalc Software Ltd., Ostend, Belgium). P-values of less than 0.05 were considered to indicate statistical significance.

Results

Patient Characteristics

This study enrolled 249 patients (male:female ratio, 107:142; mean age, 53±14 years) who underwent ultrasonography assessment using 2D-SWE and had complete laboratory findings available between April 2018 and March 2022.

Overall, 249 patients were included in the analysis, with 54 (21.7%) classified as requiring treatment (group 1) and 195 (78.3%) as not requiring treatment (group 2). The clinical characteristics of participants are detailed in Table 1. Within group 1, 23 patients exhibited LS values of 13 kPa or higher, while the remaining 31 patients were assigned based on the EASL guidelines. Of the 226 total patients with LS values below 13 kPa, 31 (13.7%) were in group 1 and 195 (86.3%) were in group 2. A flowchart illustrating the breakdown of each analysis is presented in Fig. 1.

Pearson Correlation between LS and DS

In both overall and subgroup analyses, LS and DS tended to increase concurrently. The Pearson correlation coefficient for the overall analysis was 0.716 (P<0.001), signifying a strong relationship. For the subgroup with LS <13 kPa, the Pearson correlation coefficient was 0.577 (P<0.001), indicative of a moderate relationship. Scatter plots illustrating the relationship between LS and DS for each analysis are presented in Fig. 2.

Analysis of All Patients

The mean LS values for group 1 and group 2 were 12.64±6.76 kPa and 6.31±1.67 kPa, respectively (P<0.001). The mean DS values were 15.52±4.95 (m/s)/kHz for group 1 and 11.04±1.93 (m/s)/kHz for group 2 (P<0.001) (Table 2).

Among the patients considered to require treatment (group 1), the AUC of LS was 0.855 (95% CI, 0.80 to 0.90; P<0.001). The optimal cutoff value of 7.6 kPa yielded a sensitivity of 72.9%, a specificity of 83.2%, a positive predictive value (PPV) of 53.4%, a negative predictive value (NPV) of 91.5%, and a diagnostic accuracy of 80.3%. For the same group, the AUC of DS was 0.810 (95% CI, 0.75 to 0.86; P<0.001), with the optimal cutoff of 13.0 (m/s)/kHz resulting in a sensitivity of 60.4%, specificity of 87.3%, PPV of 54.1%, NPV of 88.8%, and diagnostic accuracy of 80.3% (Table 3). No significant difference in AUC was observed between LS and DS in group 1 (P=0.148) (Fig. 3A).

All participants were further categorized based on thresholds of 7.6 kPa for LS and 13.0 (m/s)/kHz for DS, and the proportion of patients receiving treatment was calculated for each group. Among those with high LS and high DS, 67.4% (29/43) of patients were treated, whereas among patients with low LS and low DS, 7% (11/158) received treatment (Table 4).

Analysis of Patients with LS <13 kPa

The mean LS values for group 1 and group 2 were 8.05±2.12 kPa and 6.31±1.67 kPa, respectively (P<0.001). The mean DS values were 13.06±2.75 (m/s)/kHz for group 1 and 11.04±1.93 (m/s)/kHz for group 2 (P<0.001) (Table 2).

Among the patients considered to require treatment (group 1), the AUC of LS was 0.751 (95% CI, 0.69 to 0.81; P<0.001). The optimal cutoff value of 6.1 kPa yielded a sensitivity of 82.1%, a specificity of 56.1%, a PPV of 21.6%, an NPV of 94.5%, and a diagnostic accuracy of 57.1%. For the same treatment group, the AUC of DS was 0.711 (95% CI, 0.64 to 0.77; P<0.001), with the optimal cutoff of 11.0 (m/s)/kHz resulting in a sensitivity of 78.6%, specificity of 53.2%, PPV of 19.5%, NPV of 93.2%, and diagnostic accuracy of 53.1% (Table 3). No significant difference in AUC was observed between LS and DS in group 1 (P=0.413) (Fig. 3B).

All participants were further categorized based on thresholds of 6.1 kPa for LS and 11.0 m/s for DS. Among those with high LS and high DS, 29.0% (24/89) received treatment, while 5.4% (4/74) of patients with low LS and low DS were treated (Table 4). A representative case of a patient who underwent treatment is illustrated in Fig. 4.

Discussion

Selecting patients with CHB for antiviral therapy is crucial to prevent the progression to fibrosis and inflammation. Clinical guidelines, such as those established by the EASL, employ laboratory parameters to identify patients who require antiviral treatment. Additionally, 2D-SWE can be employed to assess LS and help exclude cACLD. In this study, these methods were combined and modified to establish a group of patients requiring treatment and to analyze LS and DS accordingly. Both parameters were higher in patients requiring treatment and demonstrated good diagnostic capabilities. While LS exhibited greater diagnostic power than DS, the difference was not statistically significant.

LS is a reliable parameter for evaluating the stages of liver fibrosis [18-21]. In a previous study of patients with CHB, LS measured using 2D-SWE demonstrated good diagnostic performance for identifying severe liver fibrosis (at or above stage F2) and cirrhosis, with AUCs of 0.975 and 0.912, respectively [20]. Although the present study did not utilize pathological results as a reference standard, it aimed to adopt a clinical approach for identifying patients in need of antiviral treatment. LS was useful in diagnosing patients categorized as requiring antiviral therapy, both in the overall cohort (AUC, 0.855) and in the subset of participants with LS values below 13 kPa (AUC, 0.751).

Studies of DS vary depending on the disease entity. In the present study, the cutoff value of DS for patients with LS <13 kPa was determined to be 11.0 (m/s)/kHz. This is comparable to the 10.8 (m/s)/kHz reported in liver transplantation recipients [16] and in patients with NASH [12], aligning with the cutoff value for inflammatory activity in these diseases. Additionally, DS demonstrated excellent diagnostic performance in assessing the degree of lobular inflammation in NASH, with AUCs of 0.95 for inflammation grade A1, 0.81 for A2, and 0.85 for A3 [10,11]. These results contrast with previous studies suggesting that DS did not improve the diagnostic performance for fibrosis and inflammation in CLD [18,22-24]. The discrepancy may stem from the fact that LS and DS values vary across liver diseases; thus, a combined evaluation may not be meaningful. In the context of CHB alone, as examined in the present study, DS exhibited good diagnostic power (AUC, 0.810). Relative to DS, LS displayed higher AUC values in both total and subgroup analyses; however, the differences were not statistically significant (P=0.148 and P=0.413, respectively).

Although early studies often assumed that LS is associated with fibrosis and DS with inflammation, LS and DS increase and decrease concurrently when measured using 2D-SWE and SWD. These parameters vary depending on the disease entity, such as fibrosis or inflammation [18,22-24]. Since the present study did not separately analyze the pathology for inflammation and fibrosis, the mechanism by which LS and DS increase in patients with CHB requiring treatment remains unclear. Regardless of the distinction between LS and DS, however, both parameters were relatively high in patients clinically requiring antiviral treatment. Another study examining the roles of both LS and DS in assessing the severity of fibrosis and inflammation focused on autoimmune hepatitis (AIH). The research results indicated that LS and DS, as determined using 2D-SWE and SWD, are reliable indicators of hepatic fibrosis and are useful for evaluating the response of hepatic inflammation to treatment in patients with AIH during follow-up [25]. Similarly, in patients with CHB, both LS and DS displayed statistically significant results in classifying patients by the need for antiviral treatment. Therefore, based on previous research, DS does not appear useful when considering patients with CLD collectively. However, this parameter may hold clinical utility for specific diseases, such as NASH, AIH, and CHB.

Previous research on treatment options for patients with CHB has been limited. One study suggested excluding fibrosis and potentially avoiding treatment for patients with LS measurements of 8.5 kPa or lower. It also recommended confirming fibrosis through liver biopsy in patients with LS values between 8.5 and 11 kPa before making treatment decisions [26]. In contrast, regarding the need for treatment, the present study identified cutoff values of 7.6 kPa for the entire patient cohort and 6.1 kPa for those with LS values under 13 kPa. This is notably lower than the 8.5 kPa threshold suggested by the previous study. Furthermore, the present findings indicate that 8.5% (15 of 176) of patients with LS values below 7.6 kPa received antiviral treatment, suggesting that applying the 8.5 kPa criterion could inappropriately exclude some patients who could benefit from treatment. The authors contend that defining a wider range of patients eligible for antiviral therapy could be instrumental in preventing the progression to fibrosis and cirrhosis in hepatitis B. Further research with a larger patient cohort is necessary to ascertain the optimal LS threshold for excluding treatment.

One limitation of this study was its retrospective nature, which may have introduced discrepancies between the study criteria and those used in clinical practice. Generalization of the findings is also difficult, due to the small sample size, single-center design, and uneven distribution of participant groups. Additionally, most patients did not undergo liver biopsy. However, the established treatment for hepatitis B typically relies on imaging and biochemical markers, as not all patients are candidates for biopsy. To clarify the pathological significance of LS and DS in patients with CHB, these results must be validated by larger, prospective multicenter studies.

In conclusion, LS and DS are useful tools for classifying patients with CHB according to the need for antiviral treatment. Although DS exhibited a lower diagnostic power compared to LS, the difference was not statistically significant. Accordingly, both parameters can be beneficial when assessing CHB alone.

This paper was supported by Wonkwang University in 2023.

Fig. 1. Flowchart of patients included in the study.

AST, aspartate aminotransferase; ALT, alanine aminotransferase; HBV, hepatitis B virus; LS, liver stiffness.

Fig. 2. Scatter plots and Pearson correlation coefficients for LS and DS, as determined by two-dimensional shear wave elastography.

These plots are shown for the entire cohort of patients with CHB (A), and the subset of patients with LS <13 kPa (B). LS, liver stiffness; DS, dispersion slope; CHB, chronic hepatitis B.

Fig. 3. Receiver operating characteristic curves for LS and DS as determined by two-dimensional shear wave elastography in the entire cohort of patients with CHB (A), and the subset of patients with LS <13 kPa (B).

A. AUC of LS (P<0.001) is 0.855; optimal cutoff, 7.6 kPa; sensitivity, 72.9%; specificity, 83.2%. AUC of DS (P<0.001) is 0.810; optimal cutoff, 13 [m/s]/kHz; sensitivity, 60.4%; specificity, 87.3%. No significant differences were observed between LS and DS (P=0.148). B. AUC of LS (P<0.001) is 0.751; optimal cutoff, 6.1 kPa; sensitivity, 82.1%; specificity, 56.1%. AUC of DS (P<0.001) is 0.711; optimal cutoff, 11.0 [m/ s]/kHz; sensitivity, 78.6%; specificity, 53.2%. No significant differences were observed between LS and DS (P=0.413). LS, liver stiffness; DS, dispersion slope; CHB, chronic hepatitis B; AUC, area under the receiver operating characteristic curve.

Fig. 4. A 74-year-old woman with chronic hepatitis B who received antiviral treatment (ALT 118 IU/L, HBV DNA 5,700,000 IU/mL).

Using 2D-SWE, the median LS was measured at 6.7 kPa, while the median DS was 15.6 (m/s)/kHz. ALT, alanine aminotransferase; HBV, hepatitis B virus; 2D-SWE, two-dimensional shear wave elastography; LS, liver stiffness; DS, dispersion slope.

Table 1. Patient characteristics

	Total (n=249)	Group 1 (n=54)	Group 2 (n=195)	P-value	
Liver stiffness (kPa)	7.68±4.35	12.64±6.76	6.31±1.67	<0.001	
Dispersion slope (m/s)/kHz	12.01±3.42	15.52±4.95	11.04±1.93	<0.001	
ATI (dB/cm/MHz)	0.60±0.10	0.59±0.09	0.60±0.10	0.678	
Platelet count (×103/μL)	203.37±139.63	152.52±67.30	217.47±150.77	0.004	
AST (IU/L)	56.96±87.73	127.35±143.40	37.43±48.68	<0.001	
ALT (IU/L)	54.65±95.83	136.63±172.12	31.91±33.62	<0.001	
ALP	94.45±49.26	108.65±43.24	90.51±50.10	0.024	
GGT	61.95±75.87	104.15±103.66	50.24±61.17	<0.001	
Total bilirubin (mg/dL)	1.07±1.94	2.00±3.86	0.81±0.61	<0.001	
Albumin (mg/dL)	4.14±0.61	3.78±0.71	4.24±0.54	<0.001	
HBV DNA (IU/mL)	4.08×107±1.93×108	1.07×108±2.01×108	2.22×107±1.87×108	0.007	
FIB-4 index	2.64±2.78	4.95±4.37	2.0±1.65	<0.001	
BMI	24.40±3.93	25.02±4.39	24.19±3.74	0.234	
Skin-to-liver capsule distance (mm)	14.31±3.10	14.06±4.09	14.38±2.76	0.537	
Alcohol history, n (%)	21/249 (8.4)	6/54 (11.1)	15/195 (7.7)	0.515a)	
Values are presented as mean±standard deviation unless otherwise indicated. Group 1, treatment required; group 2, no treatment required. Alcohol consumption <210 g per week for men and <140 g per week for women was considered indicative of a negative alcohol history.

ATI, attenuation imaging; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; HBV, hepatitis B virus; FIB-4, fibrosis-4; BMI, body mass index.

a) Values were obtained using the chi-square test.

Table 2. Intergroup comparisons of LS and DS

	Group 1	Group 2	P-value	
All patients (n=249)				
 No. of patients	54	195		
 LS (kPa)	12.64±6.76	6.31±1.67	<0.001	
 DS (m/s)/kHz	15.52±4.95	11.04±1.93	<0.001	
Patients with LS <13 kPa (n=226)				
 No. of patients	31	195		
 LS (kPa)	8.05±2.12	6.31±1.67	<0.001	
 DS (m/s)/kHz	13.06±2.75	11.04±1.93	<0.001	
Values are presented as mean±standard deviation.

Group 1, treatment required; group 2, no treatment required.

LS, liver stiffness; DS, dispersion slope.

Table 3. Diagnostic performance of LS and DS in patients with CHB

	AUC (95% CI)	Optimal cutoffa)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Diagnostic accuracy (%)	
All patients (n=249)								
 LS	0.855 (0.80-0.90)	7.6 kPa	72.9	83.2	53.4	91.5	80.3	
 DS	0.810 (0.75-0.86)	13.0 (m/s)/kHz	60.4	87.3	54.1	88.8	80.3	
Patients with LS <13 kPa (n=226)								
 LS	0.751 (0.69-0.81)	6.1 kPa	82.1	56.1	21.6	94.5	57.1	
 DS	0.711 (0.64-0.77)	11.0 (m/s)/kHz	78.6	53.2	19.5	93.2	53.1	
LS, liver stiffness; DS, dispersion slope; CHB, chronic hepatitis B; AUC, area under the curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.

a) The optimal cutoff value was obtained using the Youden index.

Table 4. Patient classification and treatment based on LS and DS levels

DS (m/s)/kHz	LS (kPa)	
<7.6	≥7.6	<6.1	≥6.1	
All patients (n=249)					
 <13.0	11/158 (7.0)	10/30 (33.3)	-	-	
 ≥13.0	4/18 (18.8)	29/43 (67.4)	-	-	
Patients with LS <13 kPa (n=226)					
 <11.0	-	-	4/74 (5.4)	2/28 (7.1)	
 ≥11.0	-	-	1/35 (2.9)	24/89 (27.0)	
Values are presented as patients receiving treatment/patients in category (%).

LS, liver stiffness; DS, dispersion slope.

Author Contributions

Conceptualization: Song SJ, Kim YR, Lee YH. Data acquisition: Kim YR, Lee YH, Cho EY. Data analysis or interpretation: Song SJ, Kim YR. Drafting of the manuscript: Song SJ, Kim YR. Critical revision of the manuscript: Kim YR. Approval of the final version of the manuscript: all authors.

No potential conflict of interest relevant to this article was reported.
==== Refs
References

1 Wu M Wu L Jin J Wang J Li S Zeng J Liver stiffness measured with two-dimensional shear-wave elastography is predictive of liver-related events in patients with chronic liver disease due to hepatis B viral infection Radiology 2020 295 353 360 32125254
2 Wei H Jiang HY Li M Zhang T Song B Two-dimensional shear wave elastography for significant liver fibrosis in patients with chronic hepatitis B: a systematic review and meta-analysis Eur J Radiol 2020 124 108839 31981878
3 El-Serag HB Epidemiology of viral hepatitis and hepatocellular carcinoma Gastroenterology 2012 142 1264 1273 22537432
4 European Association for the Study of the Liver EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection J Hepatol 2017 67 370 398 28427875
5 Shiha G Ibrahim A Helmy A Sarin SK Omata M Kumar A Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update Hepatol Int 2017 11 1 30
6 Rockey DC Caldwell SH Goodman ZD Nelson RC Smith AD American Association for the Study of Liver Diseases Liver biopsy Hepatology 2009 49 1017 1044 19243014
7 Jung IJ Kim SU Clinical implications of shear wave elastography in patients with chronic hepatitis B Clin Ultrasound 2018 3 45 49
8 Barr RG Wilson SR Rubens D Garcia-Tsao G Ferraioli G Update to the Society of Radiologists in ultrasound liver elastography consensus statement Radiology 2020 296 263 274 32515681
9 Chen S Urban MW Pislaru C Kinnick R Zheng Y Yao A Shearwave dispersion ultrasound vibrometry (SDUV) for measuring tissue elasticity and viscosity IEEE Trans Ultrason Ferroelectr Freq Control 2009 56 55 62 19213632
10 Sugimoto K Moriyasu F Oshiro H Takeuchi H Abe M Yoshimasu Y The role of multiparametric US of the liver for the evaluation of nonalcoholic steatohepatitis Radiology 2020 296 532 540 32573385
11 Sugimoto K Lee DH Lee JY Yu SJ Moriyasu F Sakamaki K Multiparametric US for identifying patients with high-risk NASH: a derivation and validation study Radiology 2021 301 625 634 34519576
12 Lee DH Cho EJ Bae JS Lee JY Yu SJ Kim H Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis Clin Gastroenterol Hepatol 2021 19 797 805 32450363
13 Shiina T Nightingale KR Palmeri ML Hall TJ Bamber JC Barr RG WFUMB guidelines and recommendations for clinical use of ultrasound elastography: part 1: basic principles and terminology Ultrasound Med Biol 2015 41 1126 1147 25805059
14 Zhang XQ Zeng J Jin JY Wang JF Chi YY Zheng RQ Shear-wave dispersion slope of the liver: effect of study protocol and ascites on the measurement applicability Ultrasound Med Biol 2022 48 59 67 34702641
15 Sugimoto K Moriyasu F Oshiro H Takeuchi H Yoshimasu Y Kasai Y Viscoelasticity measurement in rat livers using shear-wave US elastography Ultrasound Med Biol 2018 44 2018 2024 29936025
16 Lee DH Lee JY Bae JS Yi NJ Lee KW Suh KS Shear-wave dispersion slope from US shear-wave elastography: detection of allograft damage after liver transplantation Radiology 2019 293 327 333 31502939
17 Chan WK Chuah KH Rajaram RB Lim LL Ratnasingam J Vethakkan SR Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review J Obes Metab Syndr 2023 32 197 213 37700494
18 Zhang XQ Zheng RQ Jin JY Wang JF Zhang T Zeng J US Shear-wave elastography dispersion for characterization of chronic liver disease Radiology 2022 305 597 605 35916675
19 Song L Zhao L Deng J Meng F Wu X Lu Q Staging liver fibrosis in patients with chronic hepatitis B using two-dimensional shear wave elastography based on histopathological findings: a prospective multicenter study Quant Imaging Med Surg 2023 13 2376 2387 37064406
20 Jeon SK Lee JM Joo I Yoon JH Lee DH Han JK Two-dimensional shear wave elastography with propagation maps for the assessment of liver fibrosis and clinically significant portal hypertension in patients with chronic liver disease: a prospective study Acad Radiol 2020 27 798 806 31494001
21 Lee DH Lee ES Lee JY Bae JS Kim H Lee KB Two-dimensional-shear wave elastography with a propagation map: prospective evaluation of liver fibrosis using histopathology as the reference standard Korean J Radiol 2020 21 1317 1325 32729274
22 Deffieux T Gennisson JL Bousquet L Corouge M Cosconea S Amroun D Investigating liver stiffness and viscosity for fibrosis, steatosis and activity staging using shear wave elastography J Hepatol 2015 62 317 324 25251998
23 Chen S Sanchez W Callstrom MR Gorman B Lewis JT Sanderson SO Assessment of liver viscoelasticity by using shear waves induced by ultrasound radiation force Radiology 2013 266 964 970 23220900
24 Huwart L Sempoux C Salameh N Jamart J Annet L Sinkus R Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index Radiology 2007 245 458 466 17940304
25 Soh EG Lee YH Kim YR Yoon KH Choi KH Usefulness of 2D shear wave elastography for the evaluation of hepatic fibrosis and treatment response in patients with autoimmune hepatitis Ultrasonography 2022 41 740 749 36195317
26 Gao Y Zheng J Liang P Tong M Wang J Wu C Liver fibrosis with two-dimensional US shear-wave elastography in participants with chronic hepatitis B: a prospective multicenter study Radiology 2018 289 407 415 30040048
